Drug profile · INN
canagliflozin
INVOKANA
canagliflozin (INVOKANA) is a sodium/glucose cotransporter 2 inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — canagliflozin
- US status
- approved
- Class
- Alimentary tract and metabolism (A10)
- Route
- ORAL
- Patents
- 0
- Programs
- 7
- Data quality
- 0.89
Quick answer
canagliflozin (INVOKANA) is a sodium/glucose cotransporter 2 inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium/glucose cotransporter 2 inhibitor
Primary target: Sodium/glucose cotransporter 2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is canagliflozin?
canagliflozin (INVOKANA) is a sodium/glucose cotransporter 2 inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for canagliflozin?
INVOKANA is a marketed brand name for canagliflozin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of canagliflozin?
canagliflozin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.